Dan Spiegelman

Dan Spiegelman is a seasoned professional in biotechnology finance, currently serving as a Venture Partner at Samsara BioCapital since 2023, where they focus on financial strategy and IPO readiness for portfolio companies. They hold several board positions, including Chairman of the Audit Committee at Spruce Biosciences, Maze Therapeutics, and Kyverna Therapeutics, and previously served as a Board Member at Myriad Genetics and Opthea. Dan's extensive experience also includes a tenure as Chief Financial Officer at BioMarin and CV Therapeutics, as well as treasurer at Genentech. They earned a BA in Economics from Stanford University and pursued further education at the Stanford University Graduate School of Business.